VERU Veru Inc.

1.41
+0.12  (+9%)
Previous Close 1.29
Open 1.33
Price To Book 2.39
Market Cap 88455617
Shares 62,734,480
Volume 99,736
Short Ratio
Av. Daily Volume 152,902

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 poster at ASCO Genitourinary, February 14, 2019.
Zuclomiphene citrate
Hot flashes
NDA filing due 2H 2019.
Tadalafil and Finasteride combo
Benign prostatic hyperplasia (BPH)
Phase 1b initiation announced January 22, 2019 with data due later in 2019.
VERU-111 (bisindole)
Prostate cancer

Latest News

  1. Introducing Veru (NASDAQ:VERU), The Stock That Tanked 81%
  2. Veru to Participate in Two Investor Conferences in March
  3. Have Insiders Been Buying Veru Inc. (NASDAQ:VERU) Shares This Year?
  4. Veru Reports Strong Fiscal 2019 First Quarter Financial Results
  5. Veru Announces Scientific Presentations for Novel Prostate Cancer Drug Candidates at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium
  6. Earnings Preview: Veru (VERU) Q1 Earnings Expected to Decline
  7. Veru to Report Fiscal 2019 First-Quarter Financial Results, Host Conference Call on February 13th
  8. Veru Initiates Clinical Trial for Proprietary, Novel, First-in-Class Drug for Advanced Prostate Cancer
  9. Before You Buy Veru Inc. (NASDAQ:VERU), Consider Its Volatility
  10. Veru Announces Acceptance of Four Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2019
  11. Veru Announces Successful Bioavailability and Bioequivalence Clinical Trial for Tadalafil and Finasteride Combination Tablet for Benign Prostatic Hyperplasia
  12. Veru Reports Strong Net Revenues and Gross Profit for Fiscal 2018 Fourth-Quarter
  13. Veru to Report Fiscal Year 2018 Financial Results, Host Conference Call on December 13th
  14. What Kind Of Shareholders Own Veru Inc (NASDAQ:VERU)?
  15. Veru Announces First Patient Dosed in Bioequivalence Clinical Trial for Combination Tadalafil – Finasteride Tablet for Benign Prostatic Hyperplasia
  16. Veru Advances Novel, First-in-Class Oral Tubulin Inhibitor for Refractory Metastatic Prostate Cancer